The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close

Bagsværd, Denmark, 14 December 2024 — As of today, all regulatory closing conditions relating to the review of Novo Holdings A/S’s pending acquisition of Catalent, Inc. (Catalent), including expiry of the timing agreement in the US, have been fulfilled. Catalent is a global contract development and manufacturing organisation headquartered in New Jersey (US). The parties are now free to close the transaction, as well as Novo Nordisk’s subsequent acquisition of three Catalent manufacturing sites from Novo Holdings A/S.

The agreement to acquire the three manufacturing sites was announced on 5 February 2024. For further information, please see the company announcement here.

Novo Nordisk now expects the acquisition to be completed in the coming days.

Upon completion, the acquisition is expected to impact the financial outlook as issued on 6 November 2024, with a low single-digit negative impact on operating profit growth and to negatively impact free cash flow with the 11.7 billion USD acquisition price. The ongoing share buyback programme of 20 billion DKK is not impacted.

For 2025, the acquisition is expected to have a mid single-digit negative impact on operating profit growth. The acquisition will be mainly debt-financed, with interest payments negatively impacting net financial items. Novo Nordisk’s capital allocation priorities focus on internal growth investments, including supply chain expansions, dividends as well as external growth opportunities, including acquiring the three manufacturing sites. Consequently, Novo Nordisk is not expecting to initiate a share buyback programme in 2025.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Media:
Ambre James-Brown [phone] [e-mail]	Liz Skrbkova (US) [phone] [e-mail]
Investors:
Jacob Martin Wiborg Rode [phone] [e-mail]	David Heiberg Landsted [phone] [e-mail]
Sina Meyer [phone] [e-mail]	Ida Schaap Melvold [phone] [e-mail]
Frederik Taylor Pitter [phone] [e-mail]

Company announcement No 96 / 2024

Attachment

• PR241214-Catalent-clearance-to-close